Teligent Inc (TLGT, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Teligent Inc is a specialty generic pharmaceutical company. It markets and sells generic topical and branded generic injectable pharmaceutical products in the United States and Canada. Teligent Inc has a market cap of $168.760 million; its shares were traded at around $3.16 with and P/S ratio of 2.38.
For the last quarter Teligent Inc reported a revenue of $16.1 million, compared with the revenue of $17.94 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $67.3 million, an increase of 0.6% from last year. For the last five years Teligent Inc had an average revenue growth rate of 51.2% a year.
The reported loss per diluted share was 28 cents for the year, compared with the loss per share of $0.09 in the previous year. The Teligent Inc had an operating margin of -17.54%, compared with the operating margin of 3.8% a year before. The 10-year historical median operating margin of Teligent Inc is -27.11%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, Teligent Inc has the cash and cash equivalents of $26.7 million, compared with $66.0 million in the previous year. The long term debt was $121.0 million, compared with $111.4 million in the previous year. Teligent Inc has a financial strength rank of 4 (out of 10).
At the current stock price of $3.16, Teligent Inc is traded at 56.2% discount to its historical median P/S valuation band of $7.21. The P/S ratio of the stock is 2.38, while the historical median P/S ratio is 5.50. The stock lost 58.26% during the past 12 months.
For the complete 20-year historical financial data of TLGT, click here.
